MA30056B1 - Formulation de precurseur de medicament contre le hcv - Google Patents
Formulation de precurseur de medicament contre le hcvInfo
- Publication number
- MA30056B1 MA30056B1 MA31038A MA31038A MA30056B1 MA 30056 B1 MA30056 B1 MA 30056B1 MA 31038 A MA31038 A MA 31038A MA 31038 A MA31038 A MA 31038A MA 30056 B1 MA30056 B1 MA 30056B1
- Authority
- MA
- Morocco
- Prior art keywords
- formulation
- against hcv
- drug precursor
- precursor against
- butyryloxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
Abstract
FORMULATION DE PRECURSEUR DE MEDICAMENT CONTRE LE HCV La présente invention concerne une composition pharmaceutique comprenant une suspension solide préparée par extrusion en fusion à chaud de chlorhydrate d'isobutyrate de (2R,3S,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-l-yl)-2-azido-3,4-bis-iso-butyryloxy-tétrahydrofuran-2-ylméthyle (I) et d'un copolymère séquence de polyéthylène glycol (PEG)/polypropylène glycol (PPG).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75014605P | 2005-12-14 | 2005-12-14 | |
US83059406P | 2006-07-12 | 2006-07-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30056B1 true MA30056B1 (fr) | 2008-12-01 |
Family
ID=37806115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31038A MA30056B1 (fr) | 2005-12-14 | 2008-06-16 | Formulation de precurseur de medicament contre le hcv |
Country Status (21)
Country | Link |
---|---|
US (1) | US7795237B2 (fr) |
EP (1) | EP1962808B1 (fr) |
JP (1) | JP5649783B2 (fr) |
KR (1) | KR20080089344A (fr) |
AR (1) | AR058313A1 (fr) |
AT (1) | ATE482690T1 (fr) |
AU (1) | AU2006326130B2 (fr) |
BR (1) | BRPI0619890A2 (fr) |
CA (1) | CA2631498A1 (fr) |
CR (1) | CR10026A (fr) |
DE (1) | DE602006017257D1 (fr) |
DK (1) | DK1962808T3 (fr) |
EC (1) | ECSP088528A (fr) |
IL (1) | IL191791A (fr) |
MA (1) | MA30056B1 (fr) |
NO (1) | NO20082563L (fr) |
PL (1) | PL1962808T3 (fr) |
PT (1) | PT1962808E (fr) |
RU (1) | RU2435592C2 (fr) |
TW (1) | TWI382840B (fr) |
WO (1) | WO2007068615A2 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005072710A2 (fr) * | 2004-01-28 | 2005-08-11 | Johns Hopkins University | Medicaments et particules de transport de genes se deplaçant rapidement a travers les barrieres muqueuses |
CN101516339B (zh) * | 2006-08-16 | 2012-06-13 | 诺瓦提斯公司 | 制备高度结晶的治疗化合物的固体分散体的方法 |
DE602007012559D1 (de) * | 2006-09-08 | 2011-03-31 | Univ Johns Hopkins | H die schleimhaut |
WO2008119659A2 (fr) * | 2007-03-29 | 2008-10-09 | F. Hoffmann-La Roche Ag | Composition pharmaceutique et procédé correspondant |
ES2513415T3 (es) * | 2009-01-21 | 2014-10-27 | F. Hoffmann-La Roche Ag | Composiciones farmacéuticas que comprenden un profármaco inhibidor de la polimerasa del VHC |
AR075180A1 (es) * | 2009-01-29 | 2011-03-16 | Novartis Ag | Formulaciones orales solidas de una pirido-pirimidinona |
GB0909680D0 (en) | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
CN102725303B (zh) | 2010-01-28 | 2015-05-27 | 里博科学有限责任公司 | 作为抗hcv化合物的4’-叠氮基-核苷 |
KR101858797B1 (ko) | 2010-05-10 | 2018-05-16 | 유로-셀티큐 에스.에이. | 히드로모르폰 및 날록손을 포함하는 제약 조성물 |
CA2798885C (fr) | 2010-05-10 | 2014-11-18 | Euro-Celtique S.A. | Combinaison de granules charges de principe actif et de principes actifs supplementaires |
KR20130030261A (ko) | 2010-05-10 | 2013-03-26 | 유로-셀티큐 에스.에이. | 활성제-무함유 과립 및 그를 포함하는 정제의 제조 |
EP2635254B1 (fr) * | 2010-11-05 | 2019-05-15 | The John Hopkins University | Compositions et procédés visant à une réduction de la mucoadhérence |
EP2455068A1 (fr) * | 2010-11-09 | 2012-05-23 | F. Hoffmann-La Roche AG | Composition pharmaceutique pour le traitement d'infections par VHC |
WO2012062691A1 (fr) * | 2010-11-09 | 2012-05-18 | F. Hoffmann-La Roche Ag | Compositions pharmaceutiques pour le traitement des infections par le virus de l'hépatite c |
JP5917964B2 (ja) * | 2012-03-19 | 2016-05-18 | 富士ゼロックス株式会社 | 錠剤、錠剤の製造方法、錠剤管理装置、錠剤照合装置及びプログラム |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
EP4008355A1 (fr) * | 2012-05-03 | 2022-06-08 | Kala Pharmaceuticals, Inc. | Nanoparticules pharmaceutiques permettant un transport muqueux amélioré |
JP6360040B2 (ja) | 2012-05-03 | 2018-07-18 | カラ ファーマシューティカルズ インコーポレイテッド | 粘液浸透性被覆粒子、組成物、医薬組成物、医薬製剤、及びそれらの形成方法 |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
WO2014127214A1 (fr) | 2013-02-15 | 2014-08-21 | Kala Pharmaceuticals, Inc. | Composés thérapeutiques et utilisations de ceux-ci |
AU2014219024B2 (en) | 2013-02-20 | 2018-04-05 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
AU2014342042B2 (en) | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CN112716955A (zh) | 2013-11-13 | 2021-04-30 | 欧洲凯尔特公司 | 用于治疗疼痛和阿片样物质肠功能障碍综合征的氢***酮和纳洛酮 |
CA3036336A1 (fr) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Formes cristallines de composes therapeutiques et leurs utilisations |
BR112019004463A2 (pt) | 2016-09-08 | 2019-05-28 | Kala Pharmaceuticals Inc | formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso |
US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3381479A1 (fr) * | 2017-03-29 | 2018-10-03 | ARTOSS GmbH | Composition de support pour matériau de substitution osseuse |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1014941E (pt) * | 1996-06-26 | 2009-07-08 | Univ Texas | Formulação farmacêutica extrudível por termofusão |
DE69811233T2 (de) * | 1997-10-27 | 2003-11-20 | Merck Patent Gmbh | Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes |
CZ20033211A3 (cs) * | 2001-05-03 | 2004-09-15 | F. Hoffmann-La Roche Ag | Farmaceutická léková forma amorfního nelfinavir mesylátu |
DE10208344A1 (de) * | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Schmelzextrusion von Wirkstoffsalzen |
TWI332507B (en) * | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
US20050044529A1 (en) * | 2003-08-20 | 2005-02-24 | Microsoft Corporation | Task library of task data for a plurality of components on a computer system |
US20050048112A1 (en) * | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
-
2006
- 2006-12-04 WO PCT/EP2006/069262 patent/WO2007068615A2/fr active Application Filing
- 2006-12-04 RU RU2008128361/15A patent/RU2435592C2/ru not_active IP Right Cessation
- 2006-12-04 EP EP06830328A patent/EP1962808B1/fr active Active
- 2006-12-04 AU AU2006326130A patent/AU2006326130B2/en not_active Ceased
- 2006-12-04 AT AT06830328T patent/ATE482690T1/de active
- 2006-12-04 PL PL06830328T patent/PL1962808T3/pl unknown
- 2006-12-04 CA CA002631498A patent/CA2631498A1/fr not_active Abandoned
- 2006-12-04 BR BRPI0619890-2A patent/BRPI0619890A2/pt not_active IP Right Cessation
- 2006-12-04 KR KR1020087014073A patent/KR20080089344A/ko not_active Application Discontinuation
- 2006-12-04 DE DE602006017257T patent/DE602006017257D1/de active Active
- 2006-12-04 JP JP2008544952A patent/JP5649783B2/ja not_active Expired - Fee Related
- 2006-12-04 PT PT06830328T patent/PT1962808E/pt unknown
- 2006-12-04 DK DK06830328.8T patent/DK1962808T3/da active
- 2006-12-12 TW TW095146501A patent/TWI382840B/zh not_active IP Right Cessation
- 2006-12-12 AR ARP060105459A patent/AR058313A1/es not_active Application Discontinuation
- 2006-12-13 US US11/637,999 patent/US7795237B2/en not_active Expired - Fee Related
-
2008
- 2008-05-28 CR CR10026A patent/CR10026A/es not_active Application Discontinuation
- 2008-05-28 IL IL191791A patent/IL191791A/en not_active IP Right Cessation
- 2008-06-02 NO NO20082563A patent/NO20082563L/no not_active Application Discontinuation
- 2008-06-12 EC EC2008008528A patent/ECSP088528A/es unknown
- 2008-06-16 MA MA31038A patent/MA30056B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
RU2435592C2 (ru) | 2011-12-10 |
JP5649783B2 (ja) | 2015-01-07 |
US20070202175A1 (en) | 2007-08-30 |
PL1962808T3 (pl) | 2011-03-31 |
AR058313A1 (es) | 2008-01-30 |
TW200803873A (en) | 2008-01-16 |
EP1962808B1 (fr) | 2010-09-29 |
IL191791A0 (en) | 2008-12-29 |
TWI382840B (zh) | 2013-01-21 |
IL191791A (en) | 2011-06-30 |
US7795237B2 (en) | 2010-09-14 |
AU2006326130A1 (en) | 2007-06-21 |
DK1962808T3 (da) | 2010-11-08 |
ECSP088528A (es) | 2008-07-30 |
JP2009519289A (ja) | 2009-05-14 |
KR20080089344A (ko) | 2008-10-06 |
WO2007068615A3 (fr) | 2007-09-07 |
NO20082563L (no) | 2008-07-03 |
ATE482690T1 (de) | 2010-10-15 |
DE602006017257D1 (de) | 2010-11-11 |
PT1962808E (pt) | 2010-10-29 |
CA2631498A1 (fr) | 2007-06-21 |
AU2006326130B2 (en) | 2011-09-22 |
CR10026A (es) | 2008-07-29 |
RU2008128361A (ru) | 2010-01-20 |
BRPI0619890A2 (pt) | 2011-10-25 |
EP1962808A2 (fr) | 2008-09-03 |
WO2007068615A2 (fr) | 2007-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30056B1 (fr) | Formulation de precurseur de medicament contre le hcv | |
EA201270738A1 (ru) | Модуляторы фармакокинетических свойств лекарственных средств | |
BR0003364A (pt) | Composições farmacêuticas | |
MA29744B1 (fr) | Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree | |
GEP201706611B (en) | Amido compounds and their use as pharmaceuticals | |
EA200901393A1 (ru) | Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат | |
ATE519486T1 (de) | Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer | |
CY1112963T1 (el) | Σταθερες φαρμακευτικες συνθεσεις περιεχουσες 7-υποκατεστημενα-3,5-διυδροξυεπτανοϊκα οξεα ή 7-υποκατεστημενα-3,5-διυδροξυεπτενοϊκα οξεα | |
BRPI0615860B8 (pt) | composição farmacêutica de liberação prolongada monolítica sólida | |
MA27927A1 (fr) | Preparations pharmaceutiques | |
EP1894567A4 (fr) | Agents pharmaceutiques concomitants et leur utilisation | |
WO2005082414A3 (fr) | Médicaments associés | |
DE60138222D1 (de) | Modulierung von il-2 und il-15 vermittelten t zellantworten | |
WO2006044362A3 (fr) | Antagonistes du recepteur 1 de n-sulfonylpiperidine cannabinoide | |
WO2005075471A3 (fr) | Composes thiazole utilises en tant qu'inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase de type 1 | |
WO2005118579A3 (fr) | Composes chimiques | |
BR0107564A (pt) | Composição de gliburida | |
MXPA05007609A (es) | Antagonista de un receptor sensible al calcio. | |
EA201100752A1 (ru) | Фармацевтические пероральные композиции с пролонгированным высвобождением, включающие производные 2-оксо-1-пирролидина | |
DE60112956D1 (de) | Kristalline formen von fluvastatin sodium | |
BR9811557A (pt) | Derivados do 2-)4-aril ou heteroaril-piperazin-1-ilmetil)-1h-indol | |
WO2007064620A3 (fr) | Compositions comprenant une combinaison d'antagonistes ccr5 et cxcr4 | |
ATE459600T1 (de) | Substituierte pyrrolidin-2-one | |
ECSP066872A (es) | Tabletas desintegrantes que comprenden licarbazepina | |
ATE301463T1 (de) | Pharmazeutische zusammensetzungen enthaltend 17alpha-furanylester von 17beta-carbothioat androstanderivaten und einen muskarinrezeptorantagonist |